China's vaccine developer Clover slips in Hong Kong debut, Airdoc falls

Clover Biopharmaceuticals

05/11/2021 04:04

** Shares of Chinese COVID-19 vaccine developer Clover
Biopharmaceuticals Ltd  2197.HK  trade as low as HK$12.30 in
Hong Kong trading debut, down 8.1% from offer price
    ** Stock last down 2.8% from the offer price of HK$13.38
apiece; among the 30 most actively traded shares by turnover
    ** Sichuan, China-based vaccine developer offered 150 mln
shares in its global offering, raising net proceed of HK$1.87
bln ($240.3 mln) for R&D, production and commercialisation of
its core products  urn:newsml:reuters.com:*:nL1N2RW04J
    ** Clover has a deal to supply up to 414 million doses of
its COVID-19 vaccine through the global vaccine sharing scheme
COVAX
    ** Another new comer Beijing Airdoc Technology Co Ltd
 2251.HK  trade as low as HK$65.75 per share on debut, down
12.5% from the offer price of HK$75.10 apiece
    ** The AI-empowered retina-based early detection, diagnosis
and health risk assessment solutions provider offered 22.27 mln
share in the global offering, raising HK$1.67 bln proceed to  
develop and commercialize core products  urn:newsml:reuters.com:*:nFWN2RL1NE
    ** The Hang Seng Commerce & Industry Index  .HSNC  and Hong
Kong's healthcare index  .HSCIH  both slip 1%
    ** The Hang Seng China Enterprises Index  .HSCE  eases 0.8%
and the benchmark index  .HSI  falls 1%



($1 = 7.7829 Hong Kong dollars)

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))